Reference | Patients, n (ITT) | Treatment and Daily Dose (mg) | Change in SBP from Baseline at Endpoint (mm Hg) | Change in DBP from Baseline at Endpoint (mm Hg) | Responder Rate (%) | BP Control Rate at Endpoint (%) |
---|---|---|---|---|---|---|
Villamil (2007) [21] | 192 | Placebo | -7.5 | -6.9 | 45.8 | 28.1 |
183 | Aliskiren 75 | -9.4 | -8.7±0.59a | 51.9 | (29.0 | |
183 | Aliskiren 150 | -12.2b | -8.9±0.59a | 51.9 | to | |
180 | Aliskiren 300 | -15.7c | -10.3±0.60c | 63.9b | c 46.7) | |
194 | HCTZ 6.25 | -11.0a | -9.1±0.58a | 53.6 | (32.5 | |
188 | HCTZ 12.5 | -13.9c | -10.1±0.59c | 60.6a | to | |
173 | HCTZ 25 | -14.3c | -9.4±0.61a | 59.0a | 37.8) | |
187 | Aliskiren/HCTZ 75/6.25 | -14.3 ±0.93c,d | -10.8c,d | 61.5a | a | |
189 | Aliskiren/HCTZ 75/12.5 | -15.6c | -11.1c | 63.5b | a | |
186 | Aliskiren/HCTZ 75/25 | -17.3c,d | -11.5c,d | 70.4c,d | a,d (37.4 | |
173 | Aliskiren/HCTZ 150/6.25 | -15.3c | -10.4±0.59c | 58.4a | a to | |
184 | Aliskiren/HCTZ 150/12.5 | -17.6c,d | -11.9c,d | 69.6c | a,d 59.5) | |
187 | Aliskiren/HCTZ 150/25 | -19.5c,d | -12.7c,d | 71.1c,d | a,d | |
180 | Aliskiren/HCTZ 300/12.5 | -19.8c,d | -13.9c,d | 80.6c,d | a,d | |
173 | Aliskiren/HCTZ 300/25 | -21.2±0.97c,d | -14.3±0.61c,d | 76.9c,d | a,d | |
Jordan(2007) [22] | 117 | HCTZ 25 | -8.6±1.00 | -7.9±0.73 | 59.0 | 34.2 |
113 | Aliskiren/HCTZ 300/25 | -15.8±1.01e | -11.9±0.74e | 73.5f | 56.6g | |
117 | Irbesartan/HCTZ 300/25 | -15.4±1.00h | -11.3±0.72h | 70.9h | 54.7h | |
122 | Amlodipine/HCTZ 10/25 | -13.6±0.98h | -10.3±0.71h | 68.0h | 45.1i | |
Nickenig (2008) [20] | 296 | Aliskiren 300 | -8.0±0.9 | -7.4±0.5 | 62.2 | 40.9 |
292 | Aliskiren/HCTZ 300/12.5 | -13.5±0.9j | -10.5±0.5j | 73.3k | 57.9j | |
284 | Aliskiren/HCTZ 300/25 | -15.9±0.9j | -11.0±0.6j | 77.1j | 60.2j | |
Blumenstein (2009) [23] | 244 | HCTZ 25 mg | -7.1±0.7 | -4.8±0.4 | 47.1 | 25.8 |
242 | Aliskiren/HCTZ 150/25 | -12.9±0.7l | -8.5±0.4l | 67.4l | 48.8l | |
232 | Aliskiren/HCTZ 300/25 | -16.7±0.7l,m | -10.7±0.4l,n | 78.5l | 58.2l,o | |
Geiger (2009) [24] | 151 | HCTZ 25 | -6±1.12 | -6±0.70 | NR | 20.53 |
164 | Aliskiren/HCTZ 300/25 | -15 ±1.08l | -11±0.67l | NR | 40.85l | |
154 | Valsartan/HCTZ 320/25 | -18 ±1.12l | -14±0.70l | NR | 48.70l | |
168 | Aliskiren/Valsartan/HCTZ 300/320/25 | -22±1.07l,p,q | -16±0.67l,p,q | NR | 66.67l,p,q |